Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.79 |
| ▸ | MEN1 | O00255 | 7/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30460578 | 1.00 | KDM4E (0.79) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3490823 | 1.00 | KDM4E (0.79) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4331131 | 0.86 | KDM4E (0.69) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL13611593 | 0.86 | KDM4E (0.69) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4325470 | 0.85 | MAPT (0.70) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4325467 | 0.85 | MAPT (0.70) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4340043 | 0.84 | MAPT (0.72) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4340042 | 0.84 | MAPT (0.72) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4343479 | 0.84 | ALDH1A1 (0.71) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL13611582 | 0.84 | ALDH1A1 (0.71) | KDM4EALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486863-B2 | Activators of lateral root formation | VIB VZW (BE) | 2013-07-16 | — | — | US | claimed |
| US-20100105561-A1 | ACTIVATORS OF LATERAL ROOT FORMATION | UNIVERSITEIT GENT (BE) | 2010-04-29 | — | — | US | claimed |
| EP-2094082-A2 | ACTIVATORS OF LATERAL ROOT FORMATION | VIB VZW (BE) | 2009-09-02 | — | — | EP | claimed |
| WO-2008062035-A2 | ACTIVATORS OF LATERAL ROOT FORMATION | VIB VZW (BE) | 2008-05-29 | — | — | WO | claimed |
| US-8486863-B2 | Activators of lateral root formation | VIB VZW (BE) | 2013-07-16 | — | — | US | disclosed |
| US-8486863-B2 | Activators of lateral root formation | VIB VZW (BE) | 2013-07-16 | — | — | US | disclosed |
| US-20100105561-A1 | ACTIVATORS OF LATERAL ROOT FORMATION | UNIVERSITEIT GENT (BE) | 2010-04-29 | — | — | US | disclosed |
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| EP-2094082-A2 | ACTIVATORS OF LATERAL ROOT FORMATION | VIB VZW (BE) | 2009-09-02 | — | — | EP | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| WO-2008062035-A2 | ACTIVATORS OF LATERAL ROOT FORMATION | VIB VZW (BE) | 2008-05-29 | — | — | WO | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105561-A1 | ACTIVATORS OF LATERAL ROOT FORMATION | CROCC, ARFIP2, RALA | KDM4E 2790/4885ALDH1A1 3385/4885MEN1 4776/4885 |
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | KDM4E 3010/4885ALDH1A1 1459/4885MEN1 4874/4885 |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | KDM4E 2338/4885ALDH1A1 1173/4885MEN1 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.